Deans' stroke musings: EXPRESS: Clinical Effectiveness of Endovascular Stroke Treatment in the Early and Extended Time Windows

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Sunday, March 21, 2021

EXPRESS: Clinical Effectiveness of Endovascular Stroke Treatment in the Early and Extended Time Windows

Useless because you are not measuring 100% recovery. THAT IS THE ONLY EFFECTIVENESS ENDPOINT.

EXPRESS: Clinical Effectiveness of Endovascular Stroke Treatment in the Early and Extended Time Windows

Show all authors

Raul Nogueira, Diogo C. Haussen, David S. Liebeskind, ...

First Published March 11, 2021 Research Article

Abstract

Background

The clinical efficacy of mechanical thrombectomy (MT) has been unequivocally demonstrated in multiple randomized clinical trials (RCTs). However, these studies were performed in carefully selected centers and utilized strict inclusion criteria.

Aim

We aimed to assess the clinical effectiveness of MT in a prospective registry.

Methods

A total of 2008 patients from 76 sites across 12 countries were enrolled in a prospective open-label MT registry. Patients were categorized into the corresponding cohorts of the SWIFT-Prime, DAWN, and DEFUSE 3 trials according to the basic demographic and clinical criteria without considering specific parenchymal imaging findings. Baseline and outcome variables were compared across the corresponding groups.

Results

As compared to the treated patients in the actual trials, registry-derived patients tended to be younger and had lower baseline ASPECTS. In addition, time to treatment was earlier and the use of IV-tPA and general anesthesia were higher in DAWN- and DEFUSE 3-registry derived patients versus their corresponding trials. Reperfusion rates were higher in the registry patients. The rates of 90-day good outcome (mRS0-2) in registry-derived patients were comparable to those of the patients treated in the corresponding RCTs (SWIFT-Prime,64.5% vs 60.2%; DAWN,50.4% vs 48.6%; Beyond-DAWN:52.4% vs 48.6%; DEFUSE 3, 52% vs 44.6%, respectively; all P>0.05). Registry-derived patients had significant less disability than the corresponding RCT controls (ordinal mRS shift OR, P<0.05 for all).

Conclusion

Our study provides favorable generalizability data for the safety and efficacy of thrombectomy in the œreal-world€ setting and supports that patients may be safely treated outside the constraints of RCTs.(Safety is NOT GOOD ENOUGH. Will you please work on the only goal in stroke? 100% recovery.)

Keywords Acute stroke therapy, Stroke, Treatment, registry, thrombectomy, time